直击要害：口服抗凝剂的多效抗心律失常作用。
Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.
机构信息
Institute of Pharmacology, West-German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Germany.
Clinic for Cardiology and Angiology, West-German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Germany.
出版信息
Pharmacol Res. 2019 Jul;145:104257. doi: 10.1016/j.phrs.2019.104257. Epub 2019 May 2.
Abstract
Mechanistic understanding of atrial fibrillation (AF) pathophysiology and the complex bidirectional relationship with thromboembolic risk remains limited. Oral anticoagulation is a mainstay of AF management. An emerging concept is that anticoagulants may themselves have potential pleiotropic disease-modifying effects. We here review the available evidence for hemostasis-independent actions of the oral anticoagulants on electrical and structural remodeling, and the inflammatory component of the vulnerable substrate.
摘要
尽管人们对心房颤动 (AF) 病理生理学的机制理解以及与血栓栓塞风险的复杂双向关系仍然有限，但口服抗凝剂仍然是 AF 管理的主要方法。一个新兴的概念是，抗凝剂本身可能具有潜在的多效性疾病修饰作用。我们在这里回顾了口服抗凝剂在电重构和易损基质的炎症成分方面对止血作用以外的作用的现有证据。
相似文献
1
Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.直击要害：口服抗凝剂的多效抗心律失常作用。
Pharmacol Res. 2019 Jul;145:104257. doi: 10.1016/j.phrs.2019.104257. Epub 2019 May 2.
2
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.Xa 因子和凝血酶的多效性效应：新型抗凝剂的预期效果。
Cardiovasc Res. 2014 Mar 1;101(3):344-51. doi: 10.1093/cvr/cvt343. Epub 2014 Jan 2.
3
New drugs for atrial fibrillation.用于治疗心房颤动的新药。
J Interv Card Electrophysiol. 2008 Oct;23(1):15-21. doi: 10.1007/s10840-008-9278-2. Epub 2008 Jun 6.
4
New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation.新型和新兴的抗心律失常和抗凝药物治疗心房颤动。
Am J Health Syst Pharm. 2010 May 1;67(9 Suppl 5):S26-34. doi: 10.2146/ajhp100154.
5
Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.心房颤动与人类免疫缺陷病毒 1 型感染：系统评价。对抗凝和抗心律失常治疗的影响。
Br J Clin Pharmacol. 2019 Mar;85(3):508-515. doi: 10.1111/bcp.13837. Epub 2019 Jan 11.
6
Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.心房颤动的卒中预防：新型口服抗凝剂的影响。
Clin Appl Thromb Hemost. 2013 Jun;19(3):241-8. doi: 10.1177/1076029612458148. Epub 2012 Sep 4.
7
Pharmacologic management of atrial fibrillation: established and emerging options.心房颤动的药物治疗：既定与新兴选择
J Manag Care Pharm. 2009 Aug;15(6 Suppl B):S10-8.
8
A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.心房颤动卒中预防的新局面：关注新型抗凝药物、抗心律失常药物和器械。
Stroke. 2011 Nov;42(11):3316-22. doi: 10.1161/STROKEAHA.111.617886. Epub 2011 Oct 13.
9
[Update on current care guideline: atrial fibrillation].[当前护理指南更新：心房颤动]
Duodecim. 2014;130(12):1194-6.
10
Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.华法林很快会过时吗？心房颤动中风预防的新方法。
J Cardiovasc Pharmacol. 2008 Jul;52(1):18-27. doi: 10.1097/FJC.0b013e318177e1f2.
引用本文的文献
1
Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes.凝血酶受体PAR4在心房心肌细胞中交叉激活酪氨酸激酶c-met。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2783-2796. doi: 10.1007/s00210-024-03436-6. Epub 2024 Sep 16.
2
The thrombin receptor PAR4 supports visceral adipose tissue inflammation.凝血酶受体 PAR4 支持内脏脂肪组织炎症。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):7187-7200. doi: 10.1007/s00210-024-03097-5. Epub 2024 Apr 23.
3
Pathophysiology and clinical relevance of atrial myopathy.心房肌病的病理生理学和临床相关性。
Basic Res Cardiol. 2024 Apr;119(2):215-242. doi: 10.1007/s00395-024-01038-0. Epub 2024 Mar 12.
4
Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors.出院后早期使用预防性利伐沙班可降低新冠病毒肺炎住院幸存者长期随访期间的房颤住院率和心源性猝死发生率。
Front Pharmacol. 2023 May 30;14:1093396. doi: 10.3389/fphar.2023.1093396. eCollection 2023.
5
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.心血管不可变风险因素、合并症和合并用药与缺血/再灌注损伤的相互作用，以及药物治疗和缺血预处理的心脏保护作用。
Pharmacol Rev. 2023 Jan;75(1):159-216. doi: 10.1124/pharmrev.121.000348. Epub 2022 Dec 8.
6
Direct oral anticoagulation and severe obesity - One size fits all?直接口服抗凝药与重度肥胖——一刀切可行吗？
Int J Cardiol Heart Vasc. 2021 Dec 6;37:100923. doi: 10.1016/j.ijcha.2021.100923. eCollection 2021 Dec.
7
Stroke prevention of atrial fibrillation: Improving geographic under-use of contemporary antithrombotic approaches remains a challenge.心房颤动的中风预防：改善当代抗血栓形成方法在不同地区使用不足的情况仍然是一项挑战。
Int J Cardiol Heart Vasc. 2021 Apr 23;34:100785. doi: 10.1016/j.ijcha.2021.100785. eCollection 2021 Jun.
8
Natural history of COVID-19 and current knowledge on treatment therapeutic options.COVID-19 的自然史和当前治疗选择的治疗知识。
Biomed Pharmacother. 2020 Sep;129:110493. doi: 10.1016/j.biopha.2020.110493. Epub 2020 Jul 3.
9
Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.肝素在治疗新冠肺炎患者中的抗凝和抗心律失常作用。
J Thromb Haemost. 2020 Aug;18(8):2073-2075. doi: 10.1111/jth.14902.
10
Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation.不良影响：与直接口服抗凝剂相比，房颤患者使用维生素K拮抗剂时患骨质疏松症的风险更高。
Int J Cardiol Heart Vasc. 2020 Apr 10;27:100487. doi: 10.1016/j.ijcha.2020.100487. eCollection 2020 Apr.
本文引用的文献
1
Postoperative atrial fibrillation: mechanisms, manifestations and management.术后心房颤动：机制、表现和管理。
Nat Rev Cardiol. 2019 Jul;16(7):417-436. doi: 10.1038/s41569-019-0166-5.
2
The role of PLC-IP3 cascade on 4-aminopyridine (4-AP) contracture in electrically-driven rat atrial and diaphragmatic strips: new evidence by neomycin and heparin.磷脂酶C-肌醇三磷酸级联反应在电刺激大鼠心房和膈肌条带中4-氨基吡啶（4-AP）挛缩中的作用：新霉素和肝素提供的新证据
Cell Mol Biol (Noisy-le-grand). 2018 Oct 30;64(13):26-32.
3
Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation.伴有和不伴有心房颤动的心力衰竭患者心房的促纤维化、电活动及钙处理重塑
Front Physiol. 2018 Oct 9;9:1383. doi: 10.3389/fphys.2018.01383. eCollection 2018.
4
Role of inflammatory signaling in atrial fibrillation.炎症信号在心房颤动中的作用。
Int J Cardiol. 2019 Jul 15;287:195-200. doi: 10.1016/j.ijcard.2018.10.020. Epub 2018 Oct 4.
5
Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging.用于心房颤动的抗心律失常药物：即将出现新的进展。
Int J Cardiol Heart Vasc. 2018 Sep 13;21:11-15. doi: 10.1016/j.ijcha.2018.08.005. eCollection 2018 Dec.
6
Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis.利伐沙班通过抑制因子 Xa 调节人心房成纤维细胞的纤维化，调节一氧化氮合成和钙稳态。
J Mol Cell Cardiol. 2018 Oct;123:128-138. doi: 10.1016/j.yjmcc.2018.09.003. Epub 2018 Sep 10.
7
Cardiomyocyte Inflammasome Signaling in Cardiomyopathies and Atrial Fibrillation: Mechanisms and Potential Therapeutic Implications.心肌病和心房颤动中的心肌细胞炎性小体信号传导：机制及潜在治疗意义
Front Physiol. 2018 Aug 13;9:1115. doi: 10.3389/fphys.2018.01115. eCollection 2018.
8
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.利伐沙班治疗心力衰竭伴窦性节律和冠心病患者的疗效。
N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.
9
Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study.直接凝血酶抑制剂对大鼠 1 型糖尿病诱导的心血管功能障碍的衰减作用：一项机制研究。
Mol Cell Biochem. 2019 Jan;451(1-2):69-78. doi: 10.1007/s11010-018-3394-9. Epub 2018 Jul 3.
10
Heparin Oligosaccharides Have Antiarrhythmic Effect by Accelerating the Sodium-Calcium Exchanger.肝素寡糖通过加速钠钙交换体发挥抗心律失常作用。
Front Cardiovasc Med. 2018 Jun 7;5:67. doi: 10.3389/fcvm.2018.00067. eCollection 2018.
Zotero 插件